Clinical Trials Logo

Drug Resistant Epilepsy clinical trials

View clinical trials related to Drug Resistant Epilepsy.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT04457687 Available - Clinical trials for Drug Resistant Epilepsy

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

Start date: n/a
Phase:
Study type: Expanded Access

The primary purpose of this study is to provide continued access of lorcaserin to participants with Dravet syndrome and other refractory epilepsies.

NCT ID: NCT03676049 Available - Clinical trials for Drug Resistant Epilepsy

Cannabidiol for Drug Resistant Pediatric Epilepsy (Expanded Access Use)

Start date: n/a
Phase:
Study type: Expanded Access

This is a treatment study under an approved Expanded Use IND protocol for using Cannabidiol (CBD) Extract. CBD will be used for the treatment of 5-10 children with drug resistant epilepsy. The CBD used in this study is prepared at the University of Mississippi under approval of the National Institute on Drug Abuse (NIDA) for its preparation and FDA approval under an expanded access mechanism on a compassionate use basis. The target patient population is who would otherwise have no appropriate remaining treatment modality left. These are patients for whom the risks of a relatively untested product are outweighed by the potential benefit. Using seizure-diaries to register seizure frequency, drug log and questionnaire to measure parent/patient quality of life and side effects will be assessed in each visit. Visits are: baseline, 4, 8, and 12 weeks visit. A 24 weeks visit (6 months) will be performed if the patient is stable on therapy during the 3 initial months and want to continue on the study for 3 more months. CBD will be administered as an adjunct to all current anti-epileptic therapies.